WHSC1

NSD2
Identifiers
Aliases	NSD2, MMSET, REIIBP, TRX5, WHS, WHSC1, Wolf-Hirschhorn syndrome candidate 1, nuclear receptor binding SET domain protein 2, KMT3G, KMT3F, RAUST
External IDs	OMIM: 602952; MGI: 1276574; HomoloGene: 26175; GeneCards: NSD2; OMA:NSD2 - orthologs
Gene location (Human) Chr. Chromosome 4 (human) Band 4p16.3 Start 1,871,393 bp End 1,982,207 bp
Gene location (Mouse) Chr. Chromosome 5 (mouse) Band 5|5 B2 Start 33,978,069 bp End 34,055,319 bp
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in ventricular zone ganglionic eminence sural nerve right testis left testis secondary oocyte bone marrow cells male germ cell stromal cell of endometrium sperm Top expressed in hand superior cervical ganglion otic vesicle ventricular zone tail of embryo yolk sac lateral septal nucleus ganglionic eminence genital tubercle lateral geniculate nucleus More reference expression data BioGPS More reference expression data
Gene ontology Molecular function methyltransferase activity transferase activity sequence-specific DNA binding DNA binding histone methyltransferase activity (H4-K20 specific) chromatin binding metal ion binding protein binding histone-lysine N-methyltransferase activity DNA-binding transcription factor activity, RNA polymerase II-specific histone methyltransferase activity (H3-K36 specific) Cellular component cytoplasm nucleoplasm chromosome nucleus chromatin Biological process regulation of transcription, DNA-templated regulation of double-strand break repair via nonhomologous end joining membranous septum morphogenesis anatomical structure morphogenesis negative regulation of transcription by RNA polymerase II transcription, DNA-templated histone H3-K36 methylation atrial septum secundum morphogenesis methylation atrial septum primum morphogenesis regulation of establishment of protein localization positive regulation of isotype switching to IgA isotypes histone H4-K20 methylation bone development double-strand break repair via nonhomologous end joining chromatin organization Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 7468 107823 Ensembl ENSG00000109685 ENSMUSG00000057406 UniProt O96028 Q8BVE8 RefSeq (mRNA) NM_001042424 NM_007331 NM_014919 NM_133330 NM_133331 NM_133332 NM_133333 NM_133334 NM_133335 NM_133336 NM_001081102 NM_001177884 NM_175231 RefSeq (protein) NP_001035889 NP_015627 NP_579877 NP_579878 NP_579889 NP_579890 NP_001074571 NP_001171355 NP_780440 Location (UCSC) Chr 4: 1.87 – 1.98 Mb Chr 5: 33.98 – 34.06 Mb PubMed search
Wikidata
View/Edit Human View/Edit Mouse

Probable histone-lysine N-methyltransferase NSD2 is an enzyme that in humans is encoded by the WHSC1 gene.

This gene encodes a protein that contains four domains present in other developmental proteins: a PWWP domain, an HMG box, a SET domain, and a PHD-type zinc finger. It is expressed ubiquitously in early development.

Wolf-Hirschhorn syndrome (WHS) is a malformation syndrome associated with a hemizygous deletion of the distal short arm of chromosome 4. This gene maps to the 165 kb WHS critical region and has also been involved in the chromosomal translocation t(4;14)(p16.3;q32.3) in multiple myelomas.

Alternative splicing of this gene results in multiple transcript variants encoding different isoforms. Some transcript variants are nonsense-mediated mRNA (NMD) decay candidates, hence not represented as reference sequences.

Further reading

• Gutmajster E, Rokicka A (2003). "[Genetic determination of Wolf-Hirschhorn syndrome ]". Wiad. Lek. 55 (11–12): 706–10. PMID 12715353.
• Bergemann AD, Cole F, Hirschhorn K (2005). "The etiology of Wolf-Hirschhorn syndrome". Trends Genet. 21 (3): 188–95. doi:10.1016/j.tig.2005.01.008. PMID 15734578.
• Wright TJ, Ricke DO, Denison K, et al. (1997). "A transcript map of the newly defined 165 kb Wolf-Hirschhorn syndrome critical region". Hum. Mol. Genet. 6 (2): 317–24. doi:10.1093/hmg/6.2.317. PMID 9063753.
• Chesi M, Nardini E, Brents LA, et al. (1997). "Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3". Nat. Genet. 16 (3): 260–4. doi:10.1038/ng0797-260. PMC 3901950. PMID 9207791.
• Richelda R, Ronchetti D, Baldini L, et al. (1997). "A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene". Blood. 90 (10): 4062–70. doi:10.1182/blood.V90.10.4062. PMID 9354676.
• Kikuno R, Nagase T, Ishikawa K, et al. (1999). "Prediction of the coding sequences of unidentified human genes. XIV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro". DNA Res. 6 (3): 197–205. doi:10.1093/dnares/6.3.197. PMID 10470851.
• Malgeri U, Baldini L, Perfetti V, et al. (2000). "Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts". Cancer Res. 60 (15): 4058–61. PMID 10945609.
• Garlisi CG, Uss AS, Xiao H, et al. (2001). "A unique mRNA initiated within a middle intron of WHSC1/MMSET encodes a DNA binding protein that suppresses human IL-5 transcription". Am. J. Respir. Cell Mol. Biol. 24 (1): 90–98. doi:10.1165/ajrcmb.24.1.4224. PMID 11152655.
• Rauch A, Schellmoser S, Kraus C, et al. (2001). "First known microdeletion within the Wolf-Hirschhorn syndrome critical region refines genotype-phenotype correlation". Am. J. Med. Genet. 99 (4): 338–42. doi:10.1002/ajmg.1203. PMID 11252005.
• Perfetti V, Coluccia AM, Intini D, et al. (2001). "Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis". Am. J. Pathol. 158 (5): 1599–603. doi:10.1016/S0002-9440(10)64115-6. PMC 1891955. PMID 11337357.
• Santra M, Zhan F, Tian E, et al. (2003). "A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript". Blood. 101 (6): 2374–6. doi:10.1182/blood-2002-09-2801. PMID 12433679.
• Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
• Intini D, Fabris S, Storlazzi T, et al. (2004). "Identification of a novel IGH-MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16.3;q32) chromosomal translocation". Br. J. Haematol. 126 (3): 437–9. doi:10.1111/j.1365-2141.2004.05048.x. PMID 15257719. S2CID 38274867.
• Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
• Keats JJ, Maxwell CA, Taylor BJ, et al. (2005). "Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients". Blood. 105 (10): 4060–9. doi:10.1182/blood-2004-09-3704. PMC 1895072. PMID 15677557.
• Hudlebusch HR, Theilgaard-Mönch K, Lodahl M, et al. (2005). "Identification of ID-1 as a potential target gene of MMSET in multiple myeloma". Br. J. Haematol. 130 (5): 700–8. doi:10.1111/j.1365-2141.2005.05664.x. PMID 16115125. S2CID 24377533.